Press Releases



 
Press Releases
  Date Title View
Apr 26, 2018
REDWOOD CITY, Calif., April 26, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) has been informed of the acceptance of the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, for presentation by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The trial will be presented during the Plenary Session at the 2018 American ...
PDF
Apr 25, 2018
REDWOOD CITY, Calif., April 25, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 2 at 4:30 p.m. Eastern Time to discuss its first quarter 2018 financial results. The call and webcast will follow the release of the first quarter financial results after...
PDF
Mar 30, 2018
SAN DIEGO and REDWOOD CITY, Calif., March 30, 2018 /PRNewswire/ -- Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for the Oncotype DX® AR-V7 Nuc...
PDF
Mar 15, 2018
REDWOOD CITY, Calif., March 15, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) was informed by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, has achieved sufficient information to render a conclusion regarding the effect of chemotherapy in early-stage brea...
PDF
Mar 8, 2018
REDWOOD CITY, Calif., March 8, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2017. Total revenue was $340.8 million in the full year 2017, compared with $327.9 million in 2016, an increase of 4 percent. U.S. product revenue wa...
PDF
Feb 26, 2018
REDWOOD CITY, Calif., Feb. 26, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced the U.S. commercial launch of the Oncotype DX® AR-V7 Nucleus Detect™ test. The first and only liquid biopsy test of its kind, the Oncotype DX AR-V7 Nucleus Detect test was developed by Epic Sciences to help prolong the lives of men wit...
PDF
Feb 22, 2018
REDWOOD CITY, Calif., Feb. 22, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, March 8 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2017 financial results. The call and webcast will follow the release of the fourth quarter and year...
PDF
Feb 5, 2018
REDWOOD CITY, Calif., Feb. 5, 2018 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of real-world clinical evidence demonstrating that use of the Oncotype DX® Genomic Prostate Score™ (GPS™) test resulted in significantly higher use of active surveillance at six and 12 months compared to no testing...
PDF
Dec 21, 2017
REDWOOD CITY, Calif., Dec. 21, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 8, 2018 at 9:00 a.m. Pacific Ti...
PDF
Dec 11, 2017
REDWOOD CITY, Calif., Dec. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results of 10 studies that reinforce the unmatched value of the Oncotype DX Breast Recurrence Score® test and Oncotype DX® DCIS Score™ test in optimizing patient treatment across the breast cancer disease continuum. The data were ...
PDF
FirstPrevious
2
...
NextLast